Biohaven Pharmaceutical Holding Co. is readying for what Chief Executive Officer Vlad Coric calls a "David versus Goliath" showdown with large-cap competitor Allergan PLC in a race to sell a new class of migraine medicines.
A potential first-quarter approval of Biohaven's rimegepant, a medicine that has shown clinical success in treating migraines, would place it behind competitor Allergan's expected approval next month. However, publications in the New England Journal of Medicine and the Lancet medical journals paired with plans to use direct-to-consumer advertising may give Biohaven a leg up, Coric said.
"Telemedicine, e-commerce, social media; we're going to incorporate a modern day launch with a traditional launch as well," Coric said in an interview at Bloomberg's New York headquarters on Tuesday. "If you're prepared to run your business — that will also open up a lot of optionality," Coric added, when asked about plans for potential partnerships or deals to better compete with larger peers.